S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NASDAQ:CMPX

Compass Therapeutics (CMPX) Stock Forecast, Price & News

$3.14
+0.11 (+3.63%)
(As of 06/9/2023 ET)
Compare
Today's Range
$3.00
$3.19
50-Day Range
$2.64
$3.48
52-Week Range
$1.81
$5.65
Volume
360,551 shs
Average Volume
302,178 shs
Market Capitalization
$397.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.05

Compass Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.0% Downside
$0.00 Price Target
Short Interest
Healthy
3.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.19mentions of Compass Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$33,700 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.34) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars

Medical Sector

179th out of 988 stocks

Biological Products, Except Diagnostic Industry

24th out of 161 stocks


CMPX stock logo

About Compass Therapeutics (NASDAQ:CMPX) Stock

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CMPX Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Compass Therapeutics GAAP EPS of -$0.10
See More Headlines

CMPX Price History

CMPX Company Calendar

Last Earnings
3/15/2023
Today
6/10/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMPX
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.00
High Stock Price Forecast
$0.00
Low Stock Price Forecast
$10,000,000.00
Forecasted Upside/Downside
+188.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
0 Analysts

Profitability

Net Income
$-39,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.44 per share

Miscellaneous

Free Float
88,808,000
Market Cap
$397.24 million
Optionable
Not Optionable
Beta
0.71

Key Executives

  • Dr. Thomas J. Schuetz M.D. (Age 62)
    Ph.D., Co-Founder, CEO & Director
    Comp: $829.56k
  • Dr. Vered Bisker-Leib M.D. (Age 51)
    MBA, Ph.D., Pres & COO
    Comp: $806.43k
  • Mr. Neil L. Lerner CPA (Age 56)
    VP of Fin.
  • Mr. Jonathan Anderman J.D.
    VP, Head of Legal & Corp. Sec.
  • Anna Gifford
    Communications Mang.
  • Dr. Minori Rosales M.D. (Age 60)
    Ph.D., Sr. VP & Head of Clinical Devel.
  • Ms. Karin Herrera B.A.
    VP & Head of Clinical Operations













CMPX Stock - Frequently Asked Questions

Should I buy or sell Compass Therapeutics stock right now?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" CMPX shares.
View CMPX analyst ratings
or view top-rated stocks.

What is Compass Therapeutics' stock price forecast for 2023?

0 Wall Street analysts have issued 12-month target prices for Compass Therapeutics' stock. Their CMPX share price forecasts range from $10,000,000.00 to $0.00. On average, they expect the company's share price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for CMPX
or view top-rated stocks among Wall Street analysts.

How have CMPX shares performed in 2023?

Compass Therapeutics' stock was trading at $5.03 at the beginning of the year. Since then, CMPX stock has decreased by 37.6% and is now trading at $3.14.
View the best growth stocks for 2023 here
.

When is Compass Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our CMPX earnings forecast
.

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) released its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01.

When did Compass Therapeutics IPO?

(CMPX) raised $50 million in an IPO on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager.

What is Compass Therapeutics' stock symbol?

Compass Therapeutics trades on the NASDAQ under the ticker symbol "CMPX."

Who are Compass Therapeutics' major shareholders?

Compass Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (4.49%), Foresite Capital Management V LLC (2.75%), Braidwell LP (2.57%), Monashee Investment Management LLC (1.72%), BlackRock Inc. (1.22%) and Geode Capital Management LLC (0.70%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib.
View institutional ownership trends
.

How do I buy shares of Compass Therapeutics?

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Compass Therapeutics' stock price today?

One share of CMPX stock can currently be purchased for approximately $3.14.

How much money does Compass Therapeutics make?

Compass Therapeutics (NASDAQ:CMPX) has a market capitalization of $397.24 million. The company earns $-39,220,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Compass Therapeutics?

The official website for the company is www.compasstherapeutics.com. The company can be reached via phone at 617-500-8099 or via email at ir@compasstherapeutics.com.

This page (NASDAQ:CMPX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -